Recherche :
Recherche avancée
Références d'articles
Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life.
[Auteurs : CORTOT A, JEWELL D, THOMSEN OO]
Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial
[Auteurs : STEINHART AH, FEAGAN BG, WONG CJ ]
Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy
[Auteurs : ALLEZ M, LEMANN M, BONNET J]
Mortality and causes of death in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark.
[Auteurs : JESS T, WINTHER KV, MUNKHOL P]
NOD2/CARD15 does not influence response to infliximab in Crohn's disease.
[Auteurs : VERMEIRE S, LOUIS E, RUTGEERTS P]
Recurrence after abdominal surgery for Crohn's disease: relationship to disease site and surgical procedure
[Auteurs : BORLEY NR, MORTENSON NJ, CHAUDRY MA ]
Attitudes toward smoking and smoking behaviors of patients with Crohn's disease
[Auteurs : HILSDEN RJ, HODGINS D, CZECHOWSKY D]
Long-term results of ileal pouch-anal anastomosis for colorectal Crohn's disease
[Auteurs : REGIMBEAU JM, PANIS Y, POCARD M]
Management of Crohn's disease in adults
[Auteurs : HANAUER SB]
Prospective, randomized trial comparing laparoscopic vs. conventional surgery for refractory ileocolic Crohn's disease
[Auteurs : MILSOM JW, HAMMERHOFER KA, BÖHM B]
Post-operative maintenance of Crohn’s disease remission with 6-mercaptopurine, mesalamine or placebo: A two-year trial.
[Auteurs : HANAUER SB, KORELITZ BI, RUTGEERTS P, PEPPERCORN MA, THISTED RA, COHEN RD, PRESENT DH]
Capsule endoscopy in patients with suspected Crohn's disease and negative endoscopy.
[Auteurs : HERRERIAS JM, CAUNEDO A, RODRIGUEZ-TELLEZ M, PELLICER F, HERRERIAS JM Jr]
A randomized, double-blind, controlled withdrawal trial in Crohn’s disease patients in long-term remission on azathioprine.
[Auteurs : LEMANN M, MARY JY, COLOMBEL JF, DUCLOS B, SOULÉ JC, LEREBOURS E, MODIGLIANI R, BOUHNIK Y]
Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: A randomized, double-blind, placebo-controlled trial.
[Auteurs : RUTGEERTS P, VAN ASSCHE G, VERMEIRE S, D HAENS G, BAERT F, NOMAN M, AERDEN I, DE HERTOGH G, GEBOES K, HIELE M, D’HOORE A, PENNINCKX F]
Small bowel involvement in Crohn’s disease: a prospective comparison of wireless capsule endoscopy and computed tomography enteroclysis
[Auteurs : VODERHOLZER WA, BEINHOELZL J, ROGALLA P, MURRER S, SCHACHSCHAL G, LOCHS H, ORTNER MA]
Endoscopic balloon dilation of ileal pouch strictures.
[Auteurs : SHEN B, FAZIO VW, REMZI FH, DELANEY CP, ACHKAR JA, BENNETT A, KHANDWALA F, BRZEZINSKI A, DOUMIT J, LIU W, LASHNER BA ]
Sargramostim for active Crohn’s disease.
[Auteurs : KORZENIK JR, DIECKGRAEFE BK, VALENTINE JF, HAUSMAN DF, GILBERT MJ]
Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease
[Auteurs : MAHADEVAN U, KANE SV, SANDBORN WJ, COHEN RD, HANSON K, TERDIMAN JP, BINION DG]
Impact of the increasing use of immunosuppressants Crohn’s disease on the need for intestinal surgery.
[Auteurs : COSNES J, NION-LARMURIER I, BEAUGERIE L, AFCHAIN P, TIRET E, GENDRE JP]
Progressive multifocal leukoencephalopathy after Natalizumab therapy for Crohn’s disease.
[Auteurs : VAN ASSCHE G, VAN RANST M, SCIOT R, DUBOIS B, VERNEIRE S, NOMAN M, VERBEECK J, GEBOES K, ROBBERECHT W, RUTGEERTS P]
Natalizumab induction and maintenance therapy for Crohn’s disease.
[Auteurs : RUTGEERTS P, SANDBORN WJ, COLOMBEL JF, ENN R, FEAGAN BG, HANAUER SB, LAWRANCE IC, PANACCIONE R, SANDERS DS, SCHREIBER S, TARGAN S, VAN DEVENTER S, GOLDBLUM R, DESPAIN D, HOGGE GS]
Predictors of immunomodulator use as early therapy in pediatric Crohn's Disease.
[Auteurs : JACOBSTEIN DA, MAMULA P, MARKOWITZ JE, LEONARD M, BALDASSANO RN]
Risk factors for initial surgery in pediatric patients with Crohn’s disease.
[Auteurs : GUPTA N, COHEN SA, BOSTROM AG, KIRSCHNER BS, BALDASSANO RN, WINTER HS, FERRY GD, SMITH T, ABRAMSON O, GOLD BD, HEYMAN MB]
Infliximab Plus Azathioprine for Steroid-Dependent Crohn’s Disease Patients : A randomized Placebo-Controlled Trial.
[Auteurs : LEMANN M, MARY JY, DUCLOS B, DUPAS JL, DELCHIER JC, LAHARIE D, MOREAU J, CADIOT G, PICON L, BOUREILLE A, SOBAHNI I, COLOMBEL JF]
A meta-analysis of the yeld of capsule endoscopy compared to other diagnostic modalities in patients with non-structuring small bowel Crohn’s Disease.
[Auteurs : TUCAT Gilbert, TRIESTER SL, LEIGHTON JA, LEONTIADIS GI, GURUDU SR, FLEISCHER DE, HARA AK, HEIGH RI, SHIFF AD, SHARMA VK]
A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's
[Auteurs : FEAGAN BG, FEDORAK RN, IRVINE EJ]
A preliminary study of growth hormone therapy for Crohn's disease
[Auteurs : SLONIM AE, BULONE L, DAMORE MB]
Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease
[Auteurs : HADERSLEV KV, TJELLESEN LT, SORENSEN H]
Bowel wall thickness measured by ultrasound as a marker of Crohn's disease activity in children
[Auteurs : HABER HP, BUSH A, ZIEBACH R]
Fracture risk is increased in Crohn's disease, but not in ulcerative colitis
[Auteurs : VESTERGAARD P, KROGH K, REJNMARK L]
Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI
[Auteurs : LOCHS H, MAYER M, FLEIG WE]
Risk factors for surgery and postoperative recurrence in Crohn's disease
[Auteurs : BERNELL O, LAPIDUS A, HELLERS G]
An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease
[Auteurs : VASILIAUSKAS EA, KAM LY, ABREU-MARTIN MT]
Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort
[Auteurs : SILVERSTEIN MD, LOFTUS EV, SANDBORN WJ]
Crohn's disease severity in familial and sporadic cases
[Auteurs : CARBONNEL F, MACAIGNE G, BEAUGERIE L]
Treatment of Crohn's disease at the turn of the century
[Auteurs : BICKSTON SJ]
Screening and surveillance colonoscopy in chronic Crohn's colitis
[Auteurs : FRIEDMAN S, RUBIN PH, BORDIAN C]
Smoking cessation and the course of Crohn's disease: an intervention study
[Auteurs : COSNES J, BEAUGERIE L, CARBONNEL F]
Infliximab for the treatment of fistulas in patients with Crohn's disease
[Auteurs : RUTGEERTS P, PRESENT DH, TARGAN S]
Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease
[Auteurs : CORTOT A, COLOMBEL JF, RUTGEERTS P]
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent
[Auteurs : KEANE J, GERSHON S, WISE RP]
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
[Auteurs : RUTGEERTS P, D HAENS G]
Endoscopic mucosal biopsies are useful in distinguishing granulomatous colitis due to Crohn's disease from tuberculosis
[Auteurs : PULIMOOD AB, RAMAKRISHNA BJ, KURIAN G]
Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial
[Auteurs : D HAENS G, VAN DEVENTER S, VAN HOGEZAND R]
Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease
[Auteurs : SCREIBER S, NIKOLAUS S]
A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group
[Auteurs : CORTOT A, JEWELL D, THOMSEN OO]
Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial
[Auteurs : PRANTERA C, COTTONE M, PALLONE F]
Maladie de Crohn jéjuno-iléale diffuse : une forme séparée de la maladie ?
[Auteurs : PELLETIER Michel, TOUZE I, GOWER-ROUSSEAU C, GRANDBASTIEN B]
Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn’s disease
[Auteurs : ARDIZZONE S, MACONI G, SAMPIETRO GM, RUSSO AG, RADICE E, COLOMBO E, IMBESI V, MOLTENI M, DANELLI PG]
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group
[Auteurs : SANDBORN WJ, TREMAINEWJ, WOLF DC]
Oral contraceptive use and the clinical course of Crohn's disease: a prospective cohort study
[Auteurs : COSNES J, CARBONNEL F]
Rectum exclus au cours de la maladie de Crohn : quel est le risque de dysplasie ?
[Auteurs : LETEURTRE E, KOSUDAR P, GAMBIEZ L]
Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial
[Auteurs : EHRENPREIS ED, KANE SV, COHEN LB]
Transabdominal bowel sonography for the detection of intestinal complications in Crohn's disease
[Auteurs : GASCHE C, MOSER G, TURETSCHEK K]
Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group
[Auteurs : HELLERS G, CORTOT A, JEWELL D]
Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease
[Auteurs : PETERS M, WANITSCHKE R, PETERS M]
Side effects of azathioprine in patients with Crohn's disease.
[Auteurs : DE JONG DJ, GOULLET M, NABER TH]
Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries.
[Auteurs : LICHTENSTEIN GR, BALA M, HANAUER SB]
Virtual colonoscopy compared with conventional colonoscopy for stricturing postoperative recurrence in Crohn's disease.
[Auteurs : BIANCONE L, FIORI R, TOSTI C, MARINETTI A, CATARINACCI M, DE NIGRIS F, SIMONETTI G, PALLONE F]
Capsule endoscopy vs. push enteroscopy and enteroclysis in suspected small-bowel Crohn's disease.
[Auteurs : CHONG AK, TAYLOR A, MILLER A, HENNESSY O, CONNELL W, DESMOND P]
Trichuris suis therapy in Crohn’s disease.
[Auteurs : SUMMERS RW, ELLIOTT DE, URBAN JF, THOMPSON R]
Human Anti- Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease : the Classic-1 trial.
[Auteurs : HANAUER SB, RUTGEERTS P, FEDORAK RN, LUKAS M, MACINTOSH d, PANACCIONE R, WOLF DC, POLLACK P, SANDBORN WJ]
Clinical evolution of luminal and perianal Crohn’s disease after inducing remission with infliximab: how long should patients be treated?
[Auteurs : DOMÈNECH E, HINOJOSA J, NO P, GARCIA-PLANELLE E, CABRÉ E, BERNAL I, GASSUL M]
Predictor for disabling Crohn's disease.
[Auteurs : BEAUGERIE L, SEKSIK Ph, NION-LARMURIER I, GENDRE JP, COSNES J]
Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn’s Disease patients.
[Auteurs : AMRE DK, LU SE, COSTEA F, SEIDMAN EG]
Human anti-tumor necrosis factor monoclonal antibody (Adalimumab) in Crohn’s disease: the ClASSIC-I trial
[Auteurs : HANAUER SB, SANDBORN WJ, RUTGEERTS P, FEDORAK RN, LUKAS M, MACINTOSH d, PANACCIONE R, WOLF DC, POLLACK P]
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
[Auteurs : RUTGEERTS P, DIAMOND RH, MOHAN BALA M, OLSON A, LICHTENSTEIN GR, PATEL K, WOLF DC, SAFDI M, COLOMBEL JF, LASHNER BA , HANAUER SB]